| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Neurology (Drs. Khatri, McQuillen, and Harrington, and Ms. Schmoll), Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital; and the Department of Biostatistics (Dr. Hoffman), Medical College of Wisconsin, Milwaukee, WI.
Fifty-four patients with chronic progressive multiple sclerosis received prednisone plus oral low-dose cyclophosphamide and either true plasmapheresis (PP) or "sham" PP weekly for 20 weeks in a double-blind controlled study. Immunosuppressive drug therapy alone (sham PP group, n = 29) was associated with improvement (
one step in Kurtzke Disability Status Scale [DSS]; mean change of 1.5) in 8 and stabilization of MS in 18 patients, with this status sustained in 23 patients at follow-up, 11 months after entry. In contrast, 14 of 26 patients who received "true" PP improved ( one step in DSS; mean change of 2.6), and 11 more were stable, with these changes sustained in 23 of 26 patients at follow-up. These differences, overall, between the PP and sham PP groups were significant at p < 0.007.
Address correspondence and reprint requests to Dr. Khatri, Department of Neurology, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital. 9900 West Wisconsin Avenue, Milwaukee, WI 53226.
Accepted for publication October 24, 1984
This article has been cited by other articles:
|
|
 |
|
  B. O. Khatri, S. Man, G. Giovannoni, A. P. Koo, J-C Lee, B. Tucky, F. Lynn, S. Jurgensen, J. Woodworth, S. Goelz, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function Neurology, February 3, 2009; 72(5): 402 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. X. Garg, T. Greene, and N. W. Levin A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance Nephrol. Dial. Transplant., January 1, 2008; 23(1): 52 - 55. [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Lehmann, H.-P. Hartung, G. R. Hetzel, O. Stuve, and B. C. Kieseier Plasma exchange in neuroimmunological disorders: part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol, July 1, 2006; 63(7): 930 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Weinstock-Guttman, M Baier, R Stockton, A Weinstock, T Justinger, F Munschauer, C Brownscheidle, J Williams, E Fisher, D Miller, et al. Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis Multiple Sclerosis, October 1, 2003; 9(5): 529 - 534. [Abstract] [PDF]
|
|
|
|
|
|
R. J. Fox, E. Fisher, R. Rudick, B.O. Khatri, M.P. McQuillen, and D. S. Goodin Disease modifying therapies in multiple sclerosis Neurology, August 13, 2002; 59(3): 471 - 473. [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Clark, G. A. Rock, N. Buskard, K. H. Shumak, P. LeBlond, D. Anderson, D. M. Sutton, and for the Canadian Apheresis Group* Therapeutic Plasma Exchange: An Update from the Canadian Apheresis Group Ann Intern Med, September 21, 1999; 131(6): 453 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. O. Khatri, O. D'Cruz, G. Priesler, G. Hambrook, and D. WORTHINGTON Plasmapheresis in a Pregnant Patient With Multiple Sclerosis Arch Neurol, January 1, 1990; 47(1): 11 - 12. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Killian, R. B. Bressler, R. M. Armstrong, and D. P. Huston Controlled Pilot Trial of Monthly Intravenous Cyclophosphamide in Multiple Sclerosis Arch Neurol, January 1, 1988; 45(1): 27 - 30. [Abstract] [PDF]
|
|
|
|
|
|
D. E. Goodkin, S. Plencner, J. Palmer-Saxerud, M. Teetzen, and D. Hertsgaard Cyclophosphamide in Chronic Progressive Multiple Sclerosis: Maintenance vs Nonmaintenance Therapy Arch Neurol, August 1, 1987; 44(8): 823 - 827. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
